# China NMPA Drug Inspection - Hunan Nanguo Yaodu Traditional Chinese Medicine Pieces Co., Ltd. - yam

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hunan-nanguo-yaodu-traditional-chinese-medicine-pieces-co-ltd/a2eb5b7a-2402-4bf7-a52d-4d917551e40b/
Source feed: China

> China NMPA drug inspection for Hunan Nanguo Yaodu Traditional Chinese Medicine Pieces Co., Ltd. published February 06, 2018. Drug: yam. The Guangxi Zhuang Autonomous Region Food and Drug Administration issued its first Drug Quality Announcement of 2018 on 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Bulletin of Guangxi Zhuang Autonomous Region Food and Drug Administration (Issue 1, 2018)
- Company Name: Hunan Nanguo Yaodu Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-02-06
- Drug Name: yam
- Inspection Finding: Leachate does not meet regulations
- Action Taken: Control measures such as sealing, seizing, and suspending sales were taken, and the units that sourced the inspected goods were investigated and dealt with according to law.
- Summary: The Guangxi Zhuang Autonomous Region Food and Drug Administration issued its first Drug Quality Announcement of 2018 on February 6, 2018, following its comprehensive drug quality sampling plan. The primary objective was to strengthen drug quality supervision and ensure public medication safety across its jurisdiction. Inspections revealed that 23 batches of drugs failed to meet established quality standards. This included 7 batches of drug preparations and 16 batches of traditional Chinese medicine decoction pieces, involving multiple manufacturers and medical institutions such as Guangxi Jinhaitang Pharmaceutical Co., Ltd., Nanning Traditional Chinese Medicine Hospital, and Guangxi Jimin Pharmaceutical Co., Ltd. Notable issues for drug preparations included deficiencies in content determination for products like Hantao Leaf Tablets and Lidocaine Hydrochloride Injection, incorrect ethanol content in topical washes, and appearance defects. For traditional Chinese medicine decoction pieces, common violations involved excessive moisture, incorrect total ash content, unsatisfactory physical properties, and residual sulfur dioxide. The regulatory framework underpinning these inspections primarily involved the 2015 and 2010 editions of the Chinese Pharmacopoeia, alongside specific regional standards. In response to these findings, the Administration has mandated immediate control measures including sealing and seizing non-compliant drugs, suspending their sale, and initiating investigations. Legal punishment will be pursued against the responsible entities to uphold drug quality and safeguard public health.

Company: https://www.globalkeysolutions.net/companies/hunan-nanguo-yaodu-traditional-chinese-medicine-pieces-co-ltd/e04cc1b0-d451-4d19-bb29-a5d1f15fd19e/